Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Zimmer Biomet Holdings Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Zimmer Biomet Holdings Inc trades at $95.27 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals.
| FLRN | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $107.71 |
52-Week Low | $30.65 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though the RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Current financial ratios including P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunity exists in the steady dividend yield, but risks include potential interest rate sensitivity as highlighted in recent financial commentary. Investors should seek updated financial statements for comprehensive analysis given the missing valuation metrics.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
